Phase 1 Study of a Recombinant Mutant Protective Antigen of Bacillus anthracis

A phase 1 study of a recombinant mutant protective antigen (rPA) vaccine was conducted in 186 healthy adults aged 18 to 45 years. Volunteers were randomized to receive one of three formulations of rPA (formalin treated, alum adsorbed, or both), in 10- or 20-μg dosages each, or the licensed vaccine,...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Bellanti, Joseph A., Lin, Feng-Ying C., Chu, Chiayung, Shiloach, Joseph, Leppla, Stephen H., Benavides, German A., Karpas, Arthur, Moayeri, Mahtab, Guo, Chunyan, Robbins, John B., Schneerson, Rachel
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Microbiology 2012
Aiheet:
Vaccines
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3272932/
https://ncbi.nlm.nih.gov/pubmed/22190398
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.05556-11
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia